Targets › NR3C2
21 programs from 20 companies in 89 trials: 30 Phase 2, 23 Phase 4, 22 Phase 3, 14 Phase 1; Cardiovascular, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. (UniProt, P08235)
Open in Phaseline: the race on NR3C2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Yale University | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 4 | Heart Failure; Intracerebral Hemorrhage | Nov 2026 |
| University of Pennsylvania | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 4 | Acne | Jul 2027 |
| Insud Pharma | Drospirenone (LF111) Mineralocorticoid receptor antagonist; Progesterone receptor agonist | NR3C2, PGR | Phase 4 | Change in Bone Mineral Density; Contraception | Dec 2027 |
| Santhera Pharmaceuticals | vamorolone Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist | NR3C1, NR3C2 | Phase 4 | Duchenne Muscular Dystrophy | Sep 2028 |
| Uppsala University | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Heart Failure With Preserved Ejection Fraction | Dec 2026 |
| Bayer | Finerenone (BAY94) Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Chronic Kidney Disease; Left Ventricular Systolic Dysfunction; Primary Membranous Nephropathy; Heart Failure … | Apr 2027 |
| Washington University School of Medicine | Eplerenone Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Heart Failure With Reduced Ejection Fraction | Apr 2029 |
| The George Institute | Fludrocortisone Acetate Mineralocorticoid receptor agonist | NR3C2 | Phase 3 | Septic Shock; Aneurysmal Subarachnoid Hemorrhage | Jul 2029 |
| Central Hospital, Nancy, France | Eplerenone Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Kidney Transplantation for More Than One Year; End-stage Renal Disease | Aug 2031 |
| Assistance Publique - Hôpitaux de Paris | 9 alpha fludrocortisone Mineralocorticoid receptor agonist | NR3C2 | Phase 3 | Critical Illness Related Corticosteroids Insufficiency | – |
| University Hospital, Strasbourg, France | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Rheumatoid Arthritis | – |
| Qilu Hospital of Shandong University | spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | NCOR Gene Mutations | Dec 2026 |
| Karolinska Institutet | Eplerenone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | HFrEF - Heart Failure With Reduced Ejection Fraction | Feb 2027 |
| Massachusetts General Hospital | spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | Preeclampsia | Dec 2027 |
| Hospices Civils de Lyon | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | Arrhythmogenic Right Ventricular Dysplasia | Dec 2027 |
| Massachusetts General Hospital | Eplerenone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | Hypertension | Mar 2029 |
| National Institutes of Health Clinical Center (CC) | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | Pulmonary Arterial Hypertension | Dec 2031 |
| NHS National Waiting Times Centre Board | Eplerenone Mineralocorticoid receptor antagonist | NR3C2 | Phase 2 | Myocardial Infarction, Acute | – |
| National Institute on Drug Abuse (NIDA) | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 1 | Alcohol Use Disorder | Dec 2026 |
| Mayo Clinic | Spironolactone Mineralocorticoid receptor antagonist | NR3C2 | Phase 1 | Thoracic Aortic Aneurysm | May 2028 |
Heart Failure (5) Obstructive Sleep Apnea (4) Chronic Kidney Disease (2) Left Ventricular Systolic Dysfunction (2) Chronic Kidney Diseases (2) Hypertension (2) Prostate Cancer (2) Multiple Sclerosis (2) Cardiac Amyloidosis (2) Ulcerative Colitis (2) Pediatric HIV Infection (2) Septic Shock (2)
small molecule (21)
Massachusetts General Hospital (2) National Institutes of Health Clinical Center (CC) (1) Washington University School of Medicine (1) Bayer (1) Yale University (1) University Hospital, Strasbourg, France (1) Assistance Publique - Hôpitaux de Paris (1) Brigham and Women's Hospital (1) NHS National Waiting Times Centre Board (1) Hospices Civils de Lyon (1) Mayo Clinic (1) Karolinska Institutet (1) Santhera Pharmaceuticals (1) Uppsala University (1) Central Hospital, Nancy, France (1) National Institute on Drug Abuse (NIDA) (1) The George Institute (1) Insud Pharma (1) Qilu Hospital of Shandong University (1) University of Pennsylvania (1)
SLC5A2 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1) AGTR1 (1) IL4R (1) SLC6A4 (1) HTR2A (1) HTR2C (1) NR3C1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.